Crinetics Pharmaceuticals' stock has surged after FDA approval of Palsonify for acromegaly. Click here to read the latest ...
Significant increases in risk were linked to menopausal hormone therapy for all autoimmune diseases except Graves disease and hepatitis.
The number of medications in development to treat obesity continues to grow, and the drugs can offer health benefits for ...
BridgeBio reports second late-stage rare disease drug success, establishing new treatment potential for endocrine disorder ...
Pregnancy complications such as gestational diabetes mellitus (GDM), preeclampsia, and gestational hypertensive disorders are becoming increasingly ...
The company reported its second late-stage study success, this time with a drug that could become a new treatment standard ...
Adolescents and young adults with preexisting autoimmune disease are more likely to develop type 1 diabetes than those ...
Based on the DESTINY-Breast06 phase III trial results demonstrating statistically significant and clinically meaningful progression-free survival benefit in patients treated with Enhertu vs.
The obesity rate for adults in the U.S. dropped to 37% in 2025 after peaking at 39.9% in 2022, but diabetes has reached an ...
From the "pot-bellied" appearance to the flaws in the LDDST, Cushing's disease remains one of our most complex endocrine ...
Lipid biomarkers, including common measures such as cholesterol and triglycerides as well as newer indicators like lipoproteins, apolipoproteins, and ...
Researchers present an overview of treatment and management strategies for patients with HR+/HER2+ breast cancer, including common adverse effects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback